Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms...

Biodexa製藥發佈了有關MTX110在複發性膠質母細胞瘤中進行中MAGIC-1研究的無進展生存和總生存方面的患者更新。在一項規模較小但重要的第1期研究中，MTX110的表現超越了歷史標準...

Benzinga · 10/17 19:39

Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms Of Progression-free And Overall Survival

Biodexa製藥公司發佈了對MTX110在複發性膠質母細胞瘤中進行的MAGIC-1研究的無進展生存和總生存的患者更新。在一項規模雖小但重要的I期研究中，MTX110的表現超越了進展生存和總生存的歷史標準

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。